Chapter
Licensed
Unlicensed
Requires Authentication
9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan
-
Jui-fen Rachel Lu
You are currently not able to access this content.
You are currently not able to access this content.
Chapters in this book
- Frontmatter i
- Contents vii
- Acknowledgment ix
- Introduction 1
- 1. The Economic Value and Pricing of Personalized Medicine 9
- 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS 21
- 3. The Value of Pharmacogenomic Information 53
- 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory 87
- 5. Characterizing the Drug Development Pipeline for Precision Medicines 115
- 6. Cost Sharing in Insurance Coverage for Precision Medicine 159
- 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments 185
- 8. Physicians’ Financial Incentives to Personalize Medicine 217
- 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan 237
- 10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 273
- 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 305
- Contributors 335
- Author Index 339
- Subject Index 345
Chapters in this book
- Frontmatter i
- Contents vii
- Acknowledgment ix
- Introduction 1
- 1. The Economic Value and Pricing of Personalized Medicine 9
- 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS 21
- 3. The Value of Pharmacogenomic Information 53
- 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory 87
- 5. Characterizing the Drug Development Pipeline for Precision Medicines 115
- 6. Cost Sharing in Insurance Coverage for Precision Medicine 159
- 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments 185
- 8. Physicians’ Financial Incentives to Personalize Medicine 217
- 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan 237
- 10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 273
- 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 305
- Contributors 335
- Author Index 339
- Subject Index 345
